S
About
Paige.ai is a pioneering AI company at the forefront of computational pathology, delivering next-generation technology to solve cancer's most critical diagnostic challenges. Built on a foundation of large-scale AI models trained on over 1.5 million whole-slide images, Paige offers a comprehensive suite of clinical diagnostic tools and licensable AI infrastructure. For clinical use, Paige provides specialty suites—including Paige Prostate, Breast, GI, and PanCancer—each designed to assist pathologists in detecting, subtyping, and classifying cancers from H&E-stained tissue slides. These applications reduce diagnostic burden, improve throughput, and surface subtle cancer features that may be missed in manual review. Paige Alba is the company's proprietary multi-modal AI co-pilot, designed to integrate into pathology workflows and help unlock precision medicine by combining visual and clinical data intelligently. For life sciences organizations and researchers, Paige offers its powerful Virchow family of foundation models (Virchow, Virchow2, Virchow2G, Virchow2G-Mini) and pre-built PanCancer AI modules that enable biomarker identification, therapeutic targeting, and clinical trial design optimization—without the need for task-specific model training. OmniScreen tools provide AI-assisted prescreening and characterization capabilities, further accelerating research and clinical pipelines. Paige is purpose-built for enterprise pathology labs, pharmaceutical companies, and research institutions seeking to embed best-in-class AI into cancer diagnostics and drug development.
Key Features
- Clinical Diagnostic AI Suites: Specialty AI applications for prostate, breast, GI, and pan-cancer detection and classification from H&E-stained whole-slide images, designed to assist pathologists in their diagnostic workflow.
- Virchow Foundation Models: A family of large-scale pathology foundation models (Virchow, Virchow2, Virchow2G, Virchow2G-Mini) pre-trained on over 1.5 million slides, enabling rapid development of custom computational pathology AI without task-specific retraining.
- Paige Alba Multi-Modal Co-Pilot: A proprietary AI co-pilot that integrates multi-modal data to streamline pathology workflows, surface insights, and support precision medicine decision-making.
- Molecular Biomarker Discovery: AI-driven analysis that reveals molecular biomarkers directly from tissue samples, enabling novel therapeutic targeting and optimized clinical trial design without additional assays.
- OmniScreen Prescreening & Characterization: AI-powered screening tools that triage and characterize pathology slides at scale, accelerating both research workflows and clinical throughput.
Use Cases
- Assisting pathologists in detecting and grading prostate cancer from needle biopsy whole-slide images to reduce diagnostic errors and workload.
- Supporting classification and identification of breast cancer subtypes from biopsy and excision specimens to enable more precise treatment planning.
- Detecting and classifying benign and malignant gastrointestinal conditions across the entire GI tract using AI-powered image analysis.
- Discovering molecular biomarkers directly from tissue slides to accelerate drug target identification and precision oncology research.
- Building and deploying custom computational pathology AI models for pharmaceutical R&D by licensing Paige's Virchow foundation models and PanCancer modules.
Pros
- Massive Training Dataset: Foundation models trained on over 1.5 million slides provide unmatched coverage of cancer morphology, improving detection sensitivity and model generalizability.
- Multi-Cancer Coverage: Purpose-built suites for prostate, breast, GI, and pan-cancer use cases make Paige one of the broadest AI pathology platforms available.
- Licensable AI Infrastructure: Life sciences organizations can license Paige's foundation models and PanCancer modules to build custom AI applications without starting from scratch.
- Clinical-Grade Reliability: Paige's diagnostic applications are developed to meet high standards of clinical excellence, privacy, and security, making them suitable for regulated healthcare environments.
Cons
- Enterprise-Only Pricing: Paige does not publish pricing publicly; access requires contacting sales or requesting a trial, making it inaccessible for smaller labs or independent researchers.
- Highly Specialized Domain: The platform is exclusively designed for oncology pathology, limiting its utility outside of cancer-focused clinical and research settings.
- Infrastructure Requirements: Deploying and integrating Paige's AI applications requires compatible digital pathology infrastructure and IT resources, which may be a barrier for less digitized institutions.
Frequently Asked Questions
What is Paige.ai?
Paige.ai is an AI company specializing in computational pathology. It develops FDA-cleared AI diagnostic tools for cancer detection and classification, as well as licensable foundation models and AI modules for life sciences research and drug development.
Which cancer types does Paige support?
Paige offers dedicated AI suites for prostate, breast, and gastrointestinal cancers, as well as a PanCancer suite capable of detecting subtle cancer features across multiple tissue types, including rare cancers.
What are the Virchow foundation models?
Virchow is a family of large pathology foundation models trained on over 1.5 million whole-slide images. They are available for licensing and allow life sciences companies to build custom computational pathology AI applications without task-specific training from scratch.
What is Paige Alba?
Paige Alba is Paige's proprietary multi-modal AI co-pilot designed to integrate into pathology lab workflows. It combines visual and clinical data to support diagnostic decision-making and help unlock precision medicine capabilities.
How can life sciences companies use Paige's technology?
Life sciences organizations can license Paige's foundation models (Virchow family) and pre-built PanCancer AI modules to accelerate the development of novel computational pathology applications, identify biomarkers, and optimize clinical trial designs.
